(Q38160089)

English

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ramon Andrade de Mello

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Pedro Madureira

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonió Manuel Ferreira Araújo

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Liliana S Carvalho

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mary O'Brien

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 November 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Pharmacogenomics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1765-1777

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Personalizing medicine: strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Personalizing therapy with targeted agents in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Prognostic factors in non-small cell lung cancer: a decade of progress

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Targeting the tumor microenvironment

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Feedback within the inter-cellular communication and tumorigenesis in carcinomas

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

ErbB receptors: directing key signaling networks throughout life

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Signaling through ERBB receptors: multiple layers of diversity and control

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The epidermal growth factor receptor pathway: a model for targeted therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Are RAS mutations predictive markers of resistance to standard chemotherapy?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Hyperactive Ras in developmental disorders and cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

K-ras mutations in non-small-cell lung carcinoma: a review

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

KRAS mutations predict response to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Novel therapeutic targets in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

A mouse model for EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Tumor angiogenesis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The role of the Angiopoietins in vascular morphogenesis.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Cellular signaling by fibroblast growth factor receptors

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Fibroblast growth factor signaling in tumorigenesis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Targeting p53 to mitochondria for cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The association of telomere length and genetic variation in telomere biology genes

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

The interaction properties of costimulatory molecules revisited.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.177

21 January 2018

Identifiers

10.2217/PGS.13.177

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24192124%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38160089&oldid=1510690600"